Detalhe da pesquisa
1.
Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies.
Br J Clin Pharmacol
; 89(7): 2190-2200, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36740580
2.
Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2.
J Acquir Immune Defic Syndr
; 91(1): 73-78, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35551149
3.
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Lancet HIV
; 4(12): e536-e546, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28729158